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Considering that the non-classical HLA-G molecule has well-recognized tolerogenic prop-
erties, HLA-G expression is expected to be deleterious when present in tumor cells and in
cells chronically infected by viruses, whereas HLA-G expression is expected to be advan-
tageous in autoimmune disorders. The expression of HLA-G on tissue or peripheral blood
cells, the levels of soluble HLA-G and polymorphic sites along the gene have been studied
in several disorders. In this study, we revised the role of the molecule and polymorphic
sites along the HLA-G gene in tumors, viral hepatitis, and parasitic disorders. Overall, sev-
eral lines of evidence clearly show that the induction of HLA-G expression in tumors has
been associated with worse disease outcome and disease spread. In addition, the few
studies conducted on hepatitis and parasitic disorders indicate that HLA-G may contribute
to disease pathogenesis. Few isolated polymorphic sites, primarily located at the coding
or 3′ untranslated HLA-G region, have been evaluated in these disorders, and a complete
HLA-G typing together with the study of gene regulatory elements may further help on
the understanding of the influence of the genetic background on disease susceptibility.
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INTRODUCTION
HLA-G is a non-classical class I gene of the human Major
Histocompatility Complex (NCBI gene ID: 3135), presenting a
restricted tissue expression pattern and encoding molecules with
immune modulatory properties. This gene, firstly described by
Geraghty and colleagues in 1987 (1), presents a genetic struc-
ture that resembles other classical HLA class I genes. However,
contrary to that observed for classical class I genes (HLA-A,
-B, and -C), the HLA-G gene is quite conserved among dif-
ferent populations and within the same population, present-
ing only a few non-synonymous mutations and several varia-
tion sites characterized as synonymous modifications, intronic
variations, or variable sites at the regulatory regions [reviewed
at Ref. (2)].
HLA-G does not seem to initiate immune responses as its
classical counterparts. Instead, the HLA-G molecule is associated
with the induction of inhibitory stimuli for T and B lymphocytes
(3, 4), Natural Killer (NK) cells (3), and antigen-presenting cells
(APC) (5). The HLA-G molecule may directly interact with mul-
tiple inhibitory receptors, including ILT2/CD85j/LILRB1 (ILT2),
ILT4/CD85d/LILRB2 (ILT4), and KIR2DL4/CD158d (KIR2DL4).
The HLA-G molecule was firstly detected at the trophoblast
in the maternal fetal interface, probably modulating the maternal
immune system during pregnancy. Beyond trophoblast expres-
sion, HLA-G has been detected in few normal tissues, including
cornea (6), thymus (7), and erythroid and endothelial precursors
(8), and its upregulation has been detected in several pathological
conditions as described in the present review.
Alternative splicing is also an important characteristic of the
HLA-G gene. It may produce at least seven protein isoforms gen-
erated by alternative splicing of the primary transcript [reviewed
at Ref. (2)], in which four isoforms are membrane-bound and
three isoforms are soluble due to the lack of a transmembrane
domain.
Much effort has been made to evaluate HLA-G worldwide
variability. The HLA-G gene seems to present functional poly-
morphisms mainly in the regulatory regions, probably influencing
its expression. Considering data from at least 18 different popu-
lations (9–12) the HLA-G locus presents few frequent extended
haplotypes. These haplotypes are a combination among a small
number of very divergent promoter and 3′ untranslated region
(3′UTR) haplotypes (Figures 1 and 2), and a coding allele usually
encodes the same HLA-G molecule (Figure 3). The regulatory seg-
ments are characterized by the occurrence of several polymorphic
sites presenting high heterozygosis. Although there is no consensus
regarding where the HLA-G transcription starts (13), the polymor-
phisms at the 5′ upstream regulatory region (5′URR) have been
considered to influence HLA-G expression, mainly because of the
fact that polymorphic sites coincides with, or are close to, known
transcription factor binding sites (Figure 1) [Reviewed at Ref.
(13)]. Likewise, haplotypes at the HLA-G 3′UTR segment have
been considered influencing HLA-G expression, mainly because
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FIGURE 1 | Variation sites at the 5′ upstream regulatory region
(5′URR) of the HLA-G gene (1.4 kb upstream of ATG), as well as the
target binding sites of the described transcriptional factors. The
position of the variation sites is determined in relation to Adenine of the
initiation codon ATG. *Since there is no official nomenclature for 5′URR
haplotypes, they were designed as previously reported (10). Transcription
factors: CREB1, CAMP responsive element binding protein 1; ATF1, cyclic
AMP-dependent transcription factor ATF-1; RREB1, Ras responsive
element binding protein 1; IRF1, interferon regulatory factor 1; p50,
nuclear factor NF-κ-B p105 subunit; RFX5, DNA-binding protein RFX5 (RFX
family); PR, progesterone receptor. I, insertion of a guanine at position
−540; ∆, deletion of an adenine at position −533.
FIGURE 2 | Variation sites at the 3′ untranslated region (3′UTR) of the
HLA-G gene that may influence HLA-G expression. Polymorphic sites
associated with diseases presented in this review are underlined. Arrows
indicate polymorphic sites that have been functionally studied. *Since there is
no official nomenclature for 3′UTR haplotypes, they were designed as
previously reported (11). DEL, deletion; INS, insertion.
the fact that some polymorphic sites (such as the one at position
+3142) may influence the binding of specific microRNAs (14–
17) or may influence mRNA stability (such as the one at position
+3187) and alternative splicing (such as the 14-bp polymorphism)
(Figure 2).
The HLA-G coding region presents mainly synonymous or
intronic variation sites. Considering the most frequent HLA-G
coding haplotypes found worldwide [reviewed at Ref. (2, 18)],
only five different HLA-G full-length molecules are frequently
found, in which four are complete molecules encoded by the HLA-
G-*01:01, *01:03, *01:04, and *01:06 allele groups, and one is a
truncated molecule encoded by the HLA-G*01:05N null allele.
Although some different HLA-G molecules were detected world-
wide, they are usually quite rare and the same HLA-G coding
alleles are usually detected in every population studied so far.
Apparently, all these frequently found molecules (exception made
to the G*01:05N) present the same modulatory effects described
earlier (2). Considering that only a few extended haplotypes are
usually found, and considering that most of the HLA-G coding
alleles are associated with only one promoter or 3′UTR haplotype,
it is possible that most of the associations described so far regard-
ing HLA-G coding polymorphism and pathological conditions are
reflecting the presence of specific promoter and 3′UTR sequences
and specific HLA-G production capabilities.
In the present review, we report some diseases that have been
associated with the modulation of the HLA-G expression, with
the presence of specific HLA-G gene variation sites or both, and
whenever known, the mechanisms underlying such associations
are discussed.
TUMORS
The arisen of transformed cells and the spread of cancer cell clones
are usually controlled by the immune system cells, particularly
by the action of cytototoxic T and NK cells; however, cancer
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FIGURE 3 | Variation sites at the coding region of the HLA-G gene
from exon 1–4. Polymorphic sites associated with diseases presented in
this review are underlined. *Haplotypes presenting a global frequency
higher than 1% in worldwide populations. Amino acids: A, alanine; S,
serine; F, phenylalanine; Y, tyrosine; T, threonine; M, methionine; Q,
glutamine; R, arginine; E, glutamic acid; P, proline; H, histidine; G,
glycine; D, aspartic acid; V, valine; C, cysteine; L, leucine; I, isoleucine;
W, tryptophan. ∆, deletion.
cells have developed several strategies to evade host immune sur-
veillance. Since classical histocompatibility (HLA-A, -B, and -C)
molecules present tumor antigens to cytotoxic T cells, tumor cells
have developed strategies to escape the cytotoxic effect of T cells by
interfering with the expression of these molecules on tumor cell
surface. On the other hand, the absence of HLA classical molecules
on the surface of tumor cells triggers NK cell activity to elimi-
nate neoplastic cells. If tumor cell expresses HLA-G, the cytotoxic
activity of both T and NK cells are inhibited, facilitating tumor cell
spread. When the decreased expression of classical HLA molecules
is accompanied by an increased expression of immunomodula-
tory molecules such as HLA-G, the effective cytototoxic immune
response against tumor cells is much impoverished [reviewed at
Ref. (2)].
Although the study of HLA-G expression in tumor cells has
been widely explored [reviewed at Ref. (19–21)], the evaluation
of the HLA-G gene polymorphic sites has not been studied at the
same extent, and even rarer are the studies evaluating the relation-
ship between HLA-G tumor expression and HLA-G polymorphic
sites. Next, we highlight some peculiarities of tumors, for which
HLA-G expression (tissue or soluble levels), gene polymorphisms,
or both have been evaluated.
HLA-G EXPRESSION IN TUMORS
Increased HLA-G expression has been observed in different
tumor types, including breast cancer (22–29), hepatocellular car-
cinoma (30–33), papillary thyroid carcinoma (34, 35), follicular
thyroid carcinoma (35), follicular adenoma (35), nasopharyn-
geal carcinoma (36), neuroblastoma (37), bladder transitional
cell carcinoma (TCC) (38), melanoma (39–42), colorectal can-
cer (43–45), gastric cancer (46–48), esophageal carcinoma (49–
53), lung cancer (49, 54–57), renal cell carcinoma (58–62),
glioblastoma (63–66), acute myeloid leukemia (67, 68), and B-
cell chronic lymphocytic leukemia (69–73). Table 1 summarizes
the HLA-G expression in many types of tumors described in this
review.
In most tumors, the increased HLA-G expression has been
associated with advanced disease stages, shorter survival time,
presence of metastasis, higher tumor grade, weak host immune
response, greater tumor size, tumor recurrence, tumor invasion,
poor histological grade, lower classical HLA antigen expression,
presence of infiltrating T regulatory cells, cancer progression,
increased inflammatory cell lesion infiltration, and tumor differ-
entiation (23, 24, 26, 29–32, 34–36, 40–42, 44, 46–48, 50–54, 56,
57, 66, 69, 72, 73, 79). In other tumors, no association between
increased HLA-G expression and clinicopathological features has
been observed, including bladder TCC (38) and acute myeloid
leukemia (67, 68).
Furthermore, increased sHLA-G levels have been reported for
breast cancer (23–25, 75), hepatocellular carcinoma (31–33), pap-
illary thyroid carcinoma (76), neuroblastoma (37), melanoma
(39), colorectal cancer (49, 77), gastric cancer (47, 49), esophageal
carcinoma (49–51), lung cancer (49, 54, 55), renal cell carcinoma
(62), and acute myeloid leukemia (78). Higher sHLA-G levels have
been associated with: (i) increased number of CD4+ regulatory T
(Treg) cells in breast cancer (23), (ii) more aggressive tumor behav-
ior in papillary thyroid carcinoma (76), (iii) local or disseminated
relapse in neuroblastoma (37), (iv) advanced stages of disease and
tumor load in melanoma (39), (v) higher IL-10 production in
esophageal carcinoma (51), (vi) absence of anterior myelodyspla-
sia along with higher leukocytosis in acute myeloid leukemia (78),
and (vii) shorter survival time, high-grade tumors, higher IL-10
production, and loss of HLA classical class I molecules in patients
with lung cancer (54–56).
Interestingly, sHLA-G levels were significantly decreased in
breast cancer patients at 6 and 12 months after surgery (25). In
addition, no association between higher sHLA-G levels and clini-
copathological features has been observed in hepatocellular carci-
noma (33), colorectal cancer (77), gastric cancer (47), esophageal
carcinoma (50, 51), and renal cell carcinoma (62). On the other
hand, plasma sHLA-G levels were closely similar when bladder
TCC patients and healthy controls were compared (38).
Overall, several laboratory (increased HLA-G tumor expres-
sion, increased sHLA-G levels, increased levels of IL-10, and a
cytokine that induces HLA-G expression) and clinical (advanced
disease stages, worse prognosis, and presence of metastasis)
findings do corroborate the malefic role of HLA-G in cancer
disorders.
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Table 1 | Association between HLA-G expression and tumors.
Tumor HLA-G molecule Reference
n Expression (%) Metastasisa sHLA-G (n)
Breast cancer 36 36IHC nd nd (22)
46/39 26(E)IHC/41(S)IHC No nd (74)
58 70.7IHC nd ↑(92)ELISA (23)
235 66IHC Yes ↑(44)ELISA (24)
677 60IHC No nd (27)
nd nd nd ↑(45)ELISA (25)
38 58IHC nd nd (28)
nd nd nd ↑(120)ELISA (75)
52 59.6IHC No nd (29)
45 62IHC Yes nd (26)
Hepatocellular carcinoma 173 57IHC nd nd (30)
219 50.2IHC nd ↑(19)ELISA (31)
36 66.7WB nd ↑(36)ELISA (32)
nd nd nd ↑(80)ELISA (33)
Thyroid cancer nd nd nd ↑(183)ELISA (76)
70 44.3IHC Yes nd (34)
72 77.5IHC No nd (35)
Nasopharyngeal carcinoma 552 79.2IHC Yes nd (36)
Neuroblastoma 12 0IHC nd ↑(53)ELISA (37)
Bladder transitional cell carcinoma 75 68IHC nd Ø(15)ELISA (38)
Melanoma nd nd nd ↑(190)ELISA (39)
79 28IHC nd nd (40)
35 34.2IHC nd nd (42)
Colorectal cancer 39 87RT-PCR nd nd (43)
201 64.6IHC Yes nd (44)
nd nd nd ↑(144)ELISA (77)
nd nd nd ↑(37)ELISA (49)
251 20.3IHC nd nd (45)
Gastric cancer 160 71IHC Yes nd (46)
179 49.7IHC Yes ↑(179)ELISA (47)
nd nd nd ↑(28)ELISA (49)
52 31IHC Yes nd (48)
Esophageal carcinoma 121 90.9IHC Yes nd (52)
79 65.8IHC nd ↑(41)ELISA (50)
nd nd nd ↑(58)ELISA (49)
60 75IHC No nd (53)
60 70IHC Yes ↑(60)ELISA (51)
Lung cancer 39 26IHC nd nd (56)
106 75IHC Yes nd (57)
101 41.6IHC nd ↑(91)ELISA (54)
nd nd nd ↑(137)ELISA (55)
nd nd nd ↑(43)ELISA (49)
Renal cell carcinoma 18 61IHC nd nd (59)
38 76qPCR nd nd (61)
(Continued)
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Table 1 | Continued
Tumor HLA-G molecule Reference
n Expression (%) Metastasisa sHLA-G (n)
Clear cell renal carcinoma 12 58IHC nd nd (60)
95 46.8IHC nd ↑(16)ELISA (62)
Glioblastoma 5 80IHC nd nd (63)
26 ≥58IHC nd nd (64)
39 64IHC nd nd (65)
108 60.2IHC nd nd (66)
Acute myeloid leukemia nd nd nd ↑(75)ELISA (78)
77 45FC nd nd (67)
22 68.2FC nd nd (68)
B-cell chronic lymphocytic leukemia 47 1–54FC nd nd (69)
20 1–34FC nd nd (72)
30 35.31FC nd nd (73)
aAssociation between HLA-G expression and metastasis.
sHLA-G, soluble HLA-G; IHC, imunohistochemistry; nd, not determined; (E), breast carcinoma effusions; (S), breast carcinoma solid lesions; ↑, increased sHLA-G
levels in patients; ELISA, enzyme-linked immunosorbent assay; WB, western blotting; Ø, similar sHLA-G levels between patients and controls; RT-PCR, reverse
transcriptase-PCR; qPCR, quantitative PCR; FC, flow cytometry.
POLYMORPHIC SITES AT HLA-G GENE AND TUMORS
Several isolated segments of the HLA-G gene have been studied in
tumors, highlighting the 3′ untranslated and coding regions. Cer-
tainly, the 14-bpINS/DEL polymorphism is the most studied. In
breast cancer patients, the 14-bpDEL allele and 14-bpDEL/DEL
genotype were associated with susceptibility to breast cancer
in Southeastern Iranian (80) and Korean patients (81); how-
ever, no association has been reported for Brazilians (26). In
addition, Korean patients exhibiting the 14-bpINS/INS genotype
exhibited no HLA-G expression in breast cancer lesions (81). A
meta-analysis evaluating the role of the 14-bpINS/DEL polymor-
phism in breast cancer reports an overall cancer risk in Asian
populations (82).
The 14-bpDEL allele was associated with susceptibility to hepa-
tocellular carcinoma in Brazilian (83) and Chinese (84) patients,
but not in Korean patients (84). In addition, Chinese patients
exhibiting the 14-bpDEL/DEL genotype presented increased HLA-
G expression in hepatocellular carcinoma specimens (84). The
14-bpINS/DEL genotype was associated with decreased risk for
childhood neuroblastoma development in Australian and New
Zealand patients (85). The HLA-G 3′UTR haplotype known as
UTR-3 (86) was associated with susceptibility to acute myeloid
leukemia development in Italian patients (68).
Considering the HLA-G coding segment, the +755C/A (non-
synonymous Leu/Ile substitution at codon 110, which defines
the HLA-G*01:04 protein group) was associated with protection
against more severe nasopharyngeal carcinoma tumor stages (87).
Regarding the bladder TCC, the HLA-G*01:04:04 allele, and
the HLA-G*01:04 allelic group were associated with susceptibil-
ity to bladder TCC in smoking patients and the HLA-G*01:03
allele and the HLA-G*01:04 allelic group was associated with
protection against bladder TCC development in non-smoking
Brazilian patients. In addition, the HLA-G*01:01 allelic group
and HLA-G*01:01/G*01:01 genotype were associated with sus-
ceptibility to bladder TCC development in non-smokers. Con-
sidering the bladder TCC progression, the following associa-
tions were observed: (i) the HLA-G*01:03 allele was associ-
ated with high-grade tumors among smokers; (ii) the HLA-
G*01:01:01/G*01:01:02 genotype was associated with protection
against high-grade tumors in the whole group of patients, whereas
the same association was observed with the HLA-G*01:01 group,
but only among smokers; and (iii) the HLA-G*01:04 allele group
was associated with high-grade tumor development in smoker and
in the whole group of patients (88).
No association has been observed for: (i) HLA-G coding region
alleles in South Korean and Brazilian breast cancer patients (81,
89); (ii) 14-bpINS/DEL polymorphism in Italian patients pre-
senting thyroid cancer (76); (iii) HLA-G*01:03 allele and HLA-
G*01:05N null allele in Tunisian patients with nasopharyngeal
carcinoma (87); (iv) HLA-G*01:05N null allele with suscepti-
bility to esophagus carcinoma development in Chinese patients
(90); (v) 14-bp INS/DEL polymorphic site in Brazilian bladder
TCC patients (88); and (vi) +292A/T, +755C/A, and +1799C/T
in Australian and New Zealand childhood neuroblastoma
patients (85).
To date, HLA-G polymorphisms have not been investigated in
the context of melanoma, glioblastoma, colorectal cancer, gastric
cancer, lung cancer, and renal cell carcinoma.
Although some polymorphic sites (14-bpDEL allele) and cod-
ing region allele groups (HLA-G*01:04) have been previously asso-
ciated with increased sHLA-G levels, few convincing associations
have been reported, exception made to breast cancer for which an
extensive meta-analysis has evidenced the role of this polymor-
phic site in Asiatic patients. Since several polymorphic sites have
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been described at the HLA-G regulatory regions, exhibiting puta-
tive roles on HLA-G expression, the typing of the complete gene
and the study of the regulatory elements (transcription factors and
microRNAs) produced in the tumor environment may the helpful
to understand the mechanisms of tumor evasion mechanisms.
VIRAL HEPATITIS
Similar to tumor cells, viruses have also developed several strate-
gies to evade the cytotoxic effect of immune effector cells, including
downregulation of HLA classical class I molecules and the upreg-
ulation of non-classical molecules, or both. As a corollary, the
increased HLA-G expression, induced by the virus itself or by the
presence of an inflammatory milieu containing transcription and
post-transcription factors that positively modulate HLA-G expres-
sion, may exacerbate virus morbidity and/or patient mortality. The
influence of HLA-G has been studied in several chronic viral infec-
tions; some of them associated with neoplastic transformation,
including human immunodeficiency virus (HIV), human papil-
lomavirus (HPV), human cytomegalovirus (hCMV), and hepatitis
viruses [reviewed at Ref. (2)].
Increased HLA-G hepatocyte expression in HCV-infected liver
specimens has been associated with milder stages of fibrosis and
hemosiderin deposit (91). Besides hepatocytes, HLA-G expres-
sion was observed on mast cells present in areas of liver fibrosis
(92). Increased plasma sHLA-G levels were associated with chronic
HCV infection and with increased IL-10 and IFN-γ levels (93).
Since the treatment of mast cells with IL-10 and class I interfer-
ons induces HLA-G expression (92), infiltrating cells may play
an important role on the maintenance of chronic infection and
induction of chronic complications.
One study has associated increased HLA-G expression in hepa-
tocytes with the HBV viral load (94). Different studies asso-
ciated the increased serum/plasma sHLA-G levels with hepati-
tis B virus infection (33, 95, 96), which were associated with
increased percentage of CD4+CD25+FoxP3+ T regulatory and
HLA-G+CD14+ monocytes cells in patients exhibiting acute or
chronic hepatitis (95), active hepatitis B virus infection (33) and
HBeAg negative hepatitis, hepatocellular carcinoma, and increased
alanine aminotransferase levels (96).
Regarding the typing of HLA-G 3′UTR polymorphic sites in
HCV- and HBV-infected patients, the +3142C allele and 14-
bpDEL/+3142C haplotype were underrepresented in Brazilian
HCV-infected patients presenting sickle cells disease compared
with HCV-negative group (97). On the other hand, the 14-
bpINS/INS genotype was overrepresented in African-Brazilian
HIV+ patients co-infected with HCV (HIV+/HCV+) compared
with HIV+/HCV− patients. Regarding the HLA-G+3142 C/G
and 14-bp INS/DEL variants, no significant association has been
reported for HIV+/HCV+- (98) and HBV-infected patients (99),
respectively, when compared with their respective controls.
Considering that many viruses have developed evasion strate-
gies that are similar to cancer cells and considering that many
chronic viral disorders have been associated with cell transforma-
tion and malignancy, the expression of HLA-G in these disorders
may predict a worse outcome and greater susceptibility to cell
transformation.
PROTOZOAN PARASITE INFECTIONS
HUMANMALARIA INFECTION
Plasmodium spp. is the etiologic agent of the human malaria and
little is known about the role of HLA-G during malaria infection,
and all studies have been performed to understand the mother
to child transmission. One study reported a decreased HLA-G
expression in extravillous trophoblast of Plasmodium falciparum-
infected placentas compared to uninfected placentas. If by one
hand, HLA-G molecule is almost exclusively expressed in extravil-
lous trophoblast of healthy placenta specimens, on the other hand,
HLA-G is detected in intervillous space macrophages of Plas-
modium-infected placentas. In addition, NK cells are increased
in infected compared to uninfected placentas (100). Furthermore,
increased cord plasma levels of sHLA-G have been associated with
low birth weight and increased risk of P. falciparum infection in
infancy (101).
A family based association study performed on individuals
from Niakhar, Senegal, reported that the +3187G allele was asso-
ciated with higher transmission to children and lower level of
parasite density during asymptomatic P. falciparum infection. The
HLA-G 3′UTR haplotype known as UTR-1 was associated with a
decreased level of parasite density during asymptomatic infection
under a dominant model, whereas the HLA-G UTR-3 haplotype
was associated with an increased level of parasite density during
the follow-up and increased intensity of asymptomatic infection
under a recessive model (102).
A second family based association study also conducted on
Senegalese population has tested the association of HLA-G 3′UTR
variants with acquired anti-malarial humoral immunity. The
+3010G and+3142C alleles were overtransmitted to children with
increased total IgG and IgG1 antibodies levels against glutamate-
rich protein (GLURP) of P. falciparum, and the +3196G allele
had a preferential transmission to children with a lower IgG3
response against merozoite surface protein 2 (MSP2). The HLA-
G 3′UTR-2 haplotype was associated with a decreased IgG3
response against MSP2, suggesting a role of HLA-G on the
regulation of immune humoral response during P. falciparum
infection (103).
HUMAN AFRICAN TRYPANOSOMIASIS
Human African trypanosomiasis, also known as sleeping sick-
ness, is caused by protozoan parasites of the Trypanosoma bru-
cei species. Although no studies are available regarding HLA-G
expression, genetic studies report associations of HLA-G gene
single nucleotide variation sites with the disease. A family based
association study reported that the HLA-G 3′UTR-14-bpINS and
+3196G alleles had a preferential transmission from heterozy-
gote parents to children and were associated with susceptibility to
human African trypanosomiasis (HAT) development. In contrast,
the HLA-G 3′UTR+3003C,+3010G, and+3187G alleles showed
lower transmission from parents to children and were associated
with decreased risk of developing the disease. Regarding HLA-G
3′UTR haplotypes, UTR-2 and UTR-5 haplotypes were associated
with higher susceptibility to HAT development, whereas the HLA-
G UTR-4 haplotype was associated with decreased risk for HAT
development (104).
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AMERICAN TRYPANOSOMIASIS
The parasite Trypanosoma cruzi is the etiologic agent of Ameri-
can trypanosomiasis, also known as Chagas disease (105). In the
chronic phase, four major clinical forms are observed: (i) car-
diac that presents progressive congestive heart failure, various
cardiac arrhythmias, thromboembolic events, and sudden death;
(ii) digestive that is characterized by clinical signs of megae-
sophagus, megacolon, or both; (iii) cardiodigestive that com-
prises clinical and pathological signs of cardiac and digestive
involvement; and (iv) indeterminate that develops without evi-
dent clinical and pathological signs (106). Recently, our group
reported a decreased HLA-G expression on cardiac muscle and
colonic cells in patients presenting cardiac or digestive clinical
variants, respectively. On the other hand, no significant differ-
ences were observed regarding HLA-G expression in the esophagus
of patients with digestive form when compared to non-chagasic
patients.
Furthermore, we evaluated the polymorphic sites at the HLA-
G 3′UTR region in Brazilian chagasic patients. The +3003T
allele and +3003TT and +3187GG genotypes were overrepre-
sented, whereas the +3003C allele and +3003CT, +3010GC,
and +3042GC genotypes were underrepresented in symptomatic
patients. In addition, the+3027CC and+3035CC genotypes, and
the +3027C and +3035C alleles were associated with the diges-
tive form of Chagas disease. Regarding HLA-G 3′UTR haplotypes,
decreased UTR-4 and UTR-7 frequencies were associated with
symptomatic patients and with the digestive form, respectively.
On the other hand, UTR-13 was associated with the indeterminate
variant and UTR-14 with the cardiac form (107).
Overall, studies on the association between HLA-G and para-
sitic disorders are still scarce and only the HLA-G 3′UTR has been
evaluated.
CONCLUSION
Considering the tolerogenic properties of HLA-G and consider-
ing the aphorism that the induced expression of HLA-G may
be detrimental in tumors and chronic viral infection, the overall
findings reported is this revision corroborates this idea. Notewor-
thy, is the induced expression of HLA-G on the surface of tumor
cells, which has been associated with greater tumor morbidity,
tumor progression, and spreading. In addition, in chronic viral
infections associated with pre-neoplastic and neoplastic transfor-
mation. On the other hand, the repression of HLA-G expression
is less well studied; i.e., the decreased expression of HLA-G in
organs or conditions in which a constitutive expression of the
molecule is expected. For instance, the decreased expression of
HLA-G (placentas of P. falciparum-infected mothers or heart and
colonic specimens of Chagas disease) has been associated with
morbidity of the chronic parasitic infection.
Studies on the association of the HLA-G gene with diseases
of diverse etiology have underestimated the myriad of polymor-
phic sites present at the various gene segments and have primarily
focused on the evaluation of one or few polymorphic sites, par-
ticularly at the 3′UTR. Considering that many polymorphic sites
along the HLA-G gene can be readily performed and analyzed,
and considering the relevant role of isolated polymorphic sites
or HLA-G haplotypes on HLA-G expression, HLA-G typing on
diseases should add an additional tool on the understanding of
the role of HLA-G on disease associations.
Theoretically, polymorphic sites observed along the coding
region may modify the encoded protein and consequently the
interaction with HLA-G receptors and the formation of HLA-
G dimers that may more efficiently bind to HLA-G receptors.
Thus, a particular allele and a particular molecule could pro-
vide susceptibility or protection against a disease development;
however, such associations have not been strong enough to be
considered a disease marker, as has been observed for the classi-
cal association between HLA-B27 and ankylosing spondylitis. On
the other hand, polymorphic sites observed along the HLA-G pro-
moter and 3′UTR gene segments may modify gene expression,
accounting for disease morbidity. Unfortunately, few polymor-
phic sites along regulatory regions have extensively been evaluated
regarding their function, and probably a combination of regula-
tory transcriptional and posttranscriptional elements may account
for the final HLA-G production. Therefore, a complete gene eval-
uation together with the availability of transcription and protein
profiles may provide light to the understanding of the mechanisms
of HLA-G induction or repression in a specific disorder.
ACKNOWLEDGMENTS
This work was supported by Coordenação de Aperfeiçoamento
de Pessoal de Nível Superior [grant number CAPES/COFECUB
653/09], Conselho Nacional de Desenvolvimento Científico e
Tecnológico [CNPq Science Without Borders Program, grant
number 236754/2012-2; Special Visiting Researcher, grant num-
ber 406594/2013-9; Young Talents, grant number 401641/2013-9;
CNPq edital 71/2013, grant number 406594/2013-9; CNPq Uni-
versal, grant number 466036/2013-5; CNPq/MS/SCTIE/DECIT
No. 31/2014 – Pesquisas sobre Doença de Chagas, grant num-
ber 467157/2014-6], and Núcleo de Apoio a Pesquisa em Doenças
Inflamatórias (NAP-DIN).
REFERENCES
1. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex
class I gene that encodes a protein with a shortened cytoplasmic segment. Proc
Natl Acad Sci U S A (1987) 84(24):9145–9. doi:10.1073/pnas.84.24.9145
2. Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P.
Implications of the polymorphism of HLA-G on its function, regulation,
evolution and disease association. Cell Mol Life Sci (2011) 68(3):369–95.
doi:10.1007/s00018-010-0580-7
3. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evi-
dence to support the role of HLA-G in protecting the fetus from maternal uter-
ine natural killer cytolysis. Proc Natl Acad Sci U S A (1997) 94(21):11520–5.
doi:10.1073/pnas.94.21.11520
4. Naji A, Menier C, Morandi F, Agaugue S, Maki G, Ferretti E, et al. Bind-
ing of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell
responses. J Immunol (2014) 192(4):1536–46. doi:10.4049/jimmunol.1300438
5. Horuzsko A, Lenfant F, Munn DH, Mellor AL. Maturation of antigen-
presenting cells is compromised in HLA-G transgenic mice. Int Immunol
(2001) 13(3):385–94. doi:10.1093/intimm/13.3.385
6. Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of
HLA-G in human cornea, an immune-privileged tissue. Hum Immunol (2003)
64(11):1039–44. doi:10.1016/j.humimm.2003.08.346
7. Lefebvre S, Adrian F, Moreau P, Gourand L, Dausset J, Berrih-Aknin S, et al.
Modulation of HLA-G expression in human thymic and amniotic epithe-
lial cells. Hum Immunol (2000) 61(11):1095–101. doi:10.1016/S0198-8859(00)
00192-0
8. Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss
N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to
www.frontiersin.org February 2015 | Volume 6 | Article 9 | 7
Dias et al. HLA-G and disease association
definitive hematopoiesis. Blood (2004) 104(10):3153–60. doi:10.1182/blood-
2004-03-0809
9. Tan Z, Shon AM, Ober C. Evidence of balancing selection at the HLA-G
promoter region. Hum Mol Genet (2005) 14(23):3619–28. doi:10.1093/hmg/
ddi389
10. Castelli EC, Mendes-Junior CT, Veiga-Castelli LC, Roger M, Moreau P, Donadi
EA. A comprehensive study of polymorphic sites along the HLA-G gene: impli-
cation for gene regulation and evolution. Mol Biol Evol (2011) 28(11):3069–86.
doi:10.1093/molbev/msr138
11. Sabbagh A, Luisi P, Castelli EC, Gineau L, Courtin D, Milet J, et al. Worldwide
genetic variation at the 3’ untranslated region of the HLA-G gene: balanc-
ing selection influencing genetic diversity. Genes Immun (2014) 15(2):95–106.
doi:10.1038/gene.2013.67
12. Santos KE, Lima TH, Felicio LP, Massaro JD, Palomino GM, Silva
AC, et al. Insights on the HLA-G evolutionary history provided by a nearby
Alu insertion. Mol Biol Evol (2013) 30(11):2423–34. doi:10.1093/molbev/
mst142
13. Castelli EC, Veiga-Castelli LC, Yaghi L, Moreau P, Donadi EA. Transcriptional
and posttranscriptional regulations of the HLA-G gene. J Immunol Res (2014)
2014:734068. doi:10.1155/2014/734068
14. Tan Z, Randall G, Fan J, Camoretti-Mercado B, Brockman-Schneider R, Pan L,
et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am
J Hum Genet (2007) 81(4):829–34. doi:10.1086/521200
15. Manaster I, Goldman-Wohl D, Greenfield C, Nachmani D, Tsukerman P,
Hamani Y, et al. MiRNA-mediated control of HLA-G expression and function.
PLoS One (2012) 7(3):e33395. doi:10.1371/journal.pone.0033395
16. Castelli EC, Moreau P, Oya e Chiromatzo A, Mendes-Junior CT, Veiga-
Castelli LC, Yaghi L, et al. In silico analysis of microRNAS targeting the
HLA-G 3’ untranslated region alleles and haplotypes. Hum Immunol (2009)
70(12):1020–5. doi:10.1016/j.humimm.2009.07.028
17. Martelli-Palomino G, Pancotto JA, Muniz YC, Mendes-Junior CT, Castelli EC,
Massaro JD, et al. Polymorphic sites at the 3’ untranslated region of the HLA-G
gene are associated with differential HLA-G soluble levels in the Brazilian and
French population. PLoS One (2013) 8(10):e71742. doi:10.1371/journal.pone.
0071742
18. Castelli EC, Ramalho J, Porto IO, Lima TH, Felicio LP, Sabbagh A, et al.
Insights into HLA-G genetics provided by worldwide haplotype diversity. Front
Immunol (2014) 5:476. doi:10.3389/fimmu.2014.00476
19. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer:
do they provide tumor cells with an escape mechanism? Cancer Res (2005)
65(22):10139–44. doi:10.1158/0008-5472.CAN-05-0097
20. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to
clinical benefits. Trends Immunol (2008) 29(3):125–32. doi:10.1016/j.it.2007.
11.005
21. Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA
class I antigens in human tumors. Semin Cancer Biol (2012) 22(4):350–8.
doi:10.1016/j.semcancer.2012.03.003
22. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, et al.
Specific activation of the non-classical class I histocompatibility HLA-G anti-
gen and expression of the ILT2 inhibitory receptor in human breast cancer.
J Pathol (2002) 196(3):266–74. doi:10.1002/path.1039
23. Chen HX, Lin A, Shen CJ, Zhen R, Chen BG, Zhang X, et al. Upregulation
of human leukocyte antigen-G expression and its clinical significance in duc-
tal breast cancer. Hum Immunol (2010) 71(9):892–8. doi:10.1016/j.humimm.
2010.06.009
24. He X, Dong DD, Yie SM, Yang H, Cao M, Ye SR, et al. HLA-G expression in
human breast cancer: implications for diagnosis and prognosis, and effect on
allocytotoxic lymphocyte response after hormone treatment in vitro. Ann Surg
Oncol (2010) 17(5):1459–69. doi:10.1245/s10434-009-0891-9
25. Sayed D, Badr G, Maximous D, Mikhail NN, Abu-Tarboush F, Alhazza IM.
HLA-G and its relation to proliferation index in detection and monitoring
breast cancer patients. Tissue Antigens (2010) 75(1):40–7. doi:10.1111/j.1399-
0039.2009.01393.x
26. Ramos CS, Goncalves AS, Marinho LC, Gomes Avelino MA, Saddi VA, Lopes
AC, et al. Analysis of HLA-G gene polymorphism and protein expression
in invasive breast ductal carcinoma. Hum Immunol (2014) 75(7):667–72.
doi:10.1016/j.humimm.2014.04.005
27. de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, et al. HLA-E
and HLA-G expression in classical HLA class I-negative tumors is of prognos-
tic value for clinical outcome of early breast cancer patients. J Immunol (2010)
185(12):7452–9. doi:10.4049/jimmunol.1002629
28. Elliott RL, Jiang XP, Phillips JT, Barnett BG, Head JF. Human leukocyte anti-
gen G expression in breast cancer: role in immunosuppression. Cancer Biother
Radiopharm (2011) 26(2):153–7. doi:10.1089/cbr.2010.0924
29. da Silva GB, Silva TG, Duarte RA, Neto NL, Carrara HH, Donadi EA, et al.
Expression of the classical and nonclassical HLA molecules in breast cancer.
Int J Breast Cancer (2013) 2013:250435. doi:10.1155/2013/250435
30. Cai MY, Xu YF, Qiu SJ, Ju MJ, Gao Q, Li YW, et al. Human leukocyte antigen-G
protein expression is an unfavorable prognostic predictor of hepatocellular car-
cinoma following curative resection. Clin Cancer Res (2009) 15(14):4686–93.
doi:10.1158/1078-0432.CCR-09-0463
31. Lin A, Chen HX, Zhu CC, Zhang X, Xu HH, Zhang JG, et al. Aberrant human
leukocyte antigen-G expression and its clinical relevance in hepatocellular car-
cinoma. J Cell Mol Med (2010) 14(8):2162–71. doi:10.1111/j.1582-4934.2009.
00917.x
32. Wang Y, Ye Z, Meng XQ, Zheng SS. Expression of HLA-G in patients with
hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int (2011) 10(2):158–63.
doi:10.1016/S1499-3872(11)60025-8
33. Park Y, Park Y, Lim HS, Kim YS, Hong DJ, Kim HS. Soluble human leukocyte
antigen-G expression in hepatitis B virus infection and hepatocellular car-
cinoma. Tissue Antigens (2012) 79(2):97–103. doi:10.1111/j.1399-0039.2011.
01814.x
34. Nunes LM, Ayres FM, Francescantonio IC, Saddi VA, Avelino MA, Alen-
car Rde C, et al. Association between the HLA-G molecule and lymph node
metastasis in papillary thyroid cancer. Hum Immunol (2013) 74(4):447–51.
doi:10.1016/j.humimm.2012.12.012
35. de Figueiredo Feitosa NL, Crispim JC, Zanetti BR, Magalhaes PK, Soares CP,
Soares EG, et al. HLA-G is differentially expressed in thyroid tissues. Thyroid
(2014) 24(3):585–92. doi:10.1089/thy.2013.0246
36. Cai MB, Han HQ, Bei JX, Liu CC, Lei JJ, Cui Q, et al. Expression of human
leukocyte antigen G is associated with prognosis in nasopharyngeal carcinoma.
Int J Biol Sci (2012) 8(6):891–900. doi:10.7150/ijbs.4383
37. Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, et al. Human
neuroblastoma cells trigger an immunosuppressive program in monocytes
by stimulating soluble HLA-G release. Cancer Res (2007) 67(13):6433–41.
doi:10.1158/0008-5472.CAN-06-4588
38. Gan LH, Huang LF, Zhang X, Lin A, Xu DP, Wang Q, et al. Tumor-specific
upregulation of human leukocyte antigen-G expression in bladder transitional
cell carcinoma. Hum Immunol (2010) 71(9):899–904. doi:10.1016/j.humimm.
2010.06.012
39. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U.
Soluble human leukocyte antigen – G serum level is elevated in melanoma
patients and is further increased by interferon-alpha immunotherapy. Can-
cer (2001) 92(2):369–76. doi:10.1002/1097-0142(20010715)92:2<369::AID-
CNCR1332>3.0.CO;2-U
40. Ibrahim EC, Aractingi S, Allory Y, Borrini F, Dupuy A, Duvillard P, et al. Analy-
sis of HLA antigen expression in benign and malignant melanocytic lesions
reveals that upregulation of HLA-G expression correlates with malignant trans-
formation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer
(2004) 108(2):243–50. doi:10.1002/ijc.11456
41. Bezuhly M, Howlett A, Colp P, Conrad DM, Walsh N, Rowden G, et al. Quan-
titative HLA-G expression in metastasising and non-metastasising primary
thin cutaneous melanomas. Dermatology (2008) 217(3):281–3. doi:10.1159/
000150602
42. Fang X, Zhang X, Li J. Up-regulation of human leukocyte antigen G expres-
sion in primary cutaneous malignant melanoma associated with host-vs-tumor
immune response. J Huazhong Univ Sci Technolog Med Sci (2008) 28(2):219–21.
doi:10.1007/s11596-008-0227-1
43. Fukushima Y, Oshika Y, Nakamura M, Tokunaga T, Hatanaka H, Abe Y, et al.
Increased expression of human histocompatibility leukocyte antigen-G in col-
orectal cancer cells. Int J Mol Med (1998) 2(3):349–51.
44. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen
G expression: as a significant prognostic indicator for patients with colorectal
cancer. Mod Pathol (2007) 20(3):375–83. doi:10.1038/modpathol.3800751
Frontiers in Immunology | Immunological Tolerance February 2015 | Volume 6 | Article 9 | 8
Dias et al. HLA-G and disease association
45. Zeestraten EC, Reimers MS, Saadatmand S, Dekker JW, Liefers GJ, van den
Elsen PJ, et al. Combined analysis of HLA class I, HLA-E and HLA-G pre-
dicts prognosis in colon cancer patients. Br J Cancer (2014) 110(2):459–68.
doi:10.1038/bjc.2013.696
46. Yie SM,Yang H,Ye SR, Li K, Dong DD, Lin XM. Expression of human leukocyte
antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann
Surg Oncol (2007) 14(10):2721–9. doi:10.1245/s10434-007-9464-y
47. Du L, Xiao X, Wang C, Zhang X, Zheng N, Wang L, et al. Human leukocyte
antigen-G is closely associated with tumor immune escape in gastric can-
cer by increasing local regulatory T cells. Cancer Sci (2011) 102(7):1272–80.
doi:10.1111/j.1349-7006.2011.01951.x
48. Tuncel T, Karagoz B, Haholu A, Ozgun A, Emirzeoglu L, Bilgi O, et al.
Immunoregulatory function of HLA-G in gastric cancer. Asian Pac J Cancer
Prev (2013) 14(12):7681–4. doi:10.7314/APJCP.2013.14.12.7681
49. Cao M, Yie SM, Liu J, Ye SR, Xia D, Gao E. Plasma soluble HLA-G is a poten-
tial biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer.
Tissue Antigens (2011) 78(2):120–8. doi:10.1111/j.1399-0039.2011.01716.x
50. Lin A, Zhang X, Zhou WJ, Ruan YY, Xu DP, Wang Q, et al. Human leuko-
cyte antigen-G expression is associated with a poor prognosis in patients with
esophageal squamous cell carcinoma. Int J Cancer (2011) 129(6):1382–90.
doi:10.1002/ijc.25807
51. Zheng J, Xu C, Chu D, Zhang X, Li J, Ji G, et al. Human leukocyte antigen G
is associated with esophageal squamous cell carcinoma progression and poor
prognosis. Immunol Lett (2014) 161(1):13–9. doi:10.1016/j.imlet.2014.04.007
52. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of HLA-G is associ-
ated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol
(2007) 128(6):1002–9. doi:10.1309/JNCW1QLDFB6AM9WE
53. Hu J, Li L, Liu Y, Chen Y, Liu C, Liang W, et al. Overexpression of HLA-G Is posi-
tively associated with Kazakh esophageal squamous cell carcinoma in Xinjiang,
China. Viral Immunol (2013) 26(3):180–4. doi:10.1089/vim.2012.0085
54. Lin A, Zhu CC, Chen HX, Chen BF, Zhang X, Zhang JG, et al. Clinical rel-
evance and functional implications for human leukocyte antigen-g expres-
sion in non-small-cell lung cancer. J Cell Mol Med (2010) 14(9):2318–29.
doi:10.1111/j.1582-4934.2009.00858.x
55. Schutt P, Schutt B, Switala M, Bauer S, Stamatis G, Opalka B, et al. Prognos-
tic relevance of soluble human leukocyte antigen-G and total human leuko-
cyte antigen class I molecules in lung cancer patients. Hum Immunol (2010)
71(5):489–95. doi:10.1016/j.humimm.2010.02.015
56. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, et al.
Human leukocyte antigen G up-regulation in lung cancer associates with
high-grade histology, human leukocyte antigen class I loss and interleukin-10
production. Am J Pathol (2001) 159(3):817–24. doi:10.1016/S0002-9440(10)
61756-7
57. Yie SM,Yang H,Ye SR, Li K, Dong DD, Lin XM. Expression of human leukocyte
antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer.
Lung Cancer (2007) 58(2):267–74. doi:10.1016/j.lungcan.2007.06.011
58. Hanak L, Slaby O, Lauerova L, Kren L, Nenutil R, Michalek J. Expression pat-
tern of HLA class I antigens in renal cell carcinoma and primary cell line cul-
tures: methodological implications for immunotherapy. Med Sci Monit (2009)
15(12):CR638–43.
59. Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED,
et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen
expression in renal carcinoma. Cancer Res (2001) 61(18):6838–45.
60. Ibrahim EC, Allory Y, Commo F, Gattegno B, Callard P, Paul P. Altered pattern
of major histocompatibility complex expression in renal carcinoma: tumor-
specific expression of the nonclassical human leukocyte antigen-G molecule is
restricted to clear cell carcinoma while up-regulation of other major histocom-
patibility complex antigens is primarily distributed in all subtypes of renal car-
cinoma. Am J Pathol (2003) 162(2):501–8. doi:10.1016/S0002-9440(10)63844-
8
61. Kren L, Valkovsky I, Dolezel J, Capak I, Pacik D, Poprach A, et al. HLA-G and
HLA-E specific mRNAs connote opposite prognostic significance in renal cell
carcinoma. Diagn Pathol (2012) 7:58. doi:10.1186/1746-1596-7-58
62. Li BL, Lin A, Zhang XJ, Zhang X, Zhang JG, Wang Q, et al. Characteriza-
tion of HLA-G expression in renal cell carcinoma. Tissue Antigens (2009)
74(3):213–21. doi:10.1111/j.1399-0039.2009.01302.x
63. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Mey-
ermann R, et al. A functional role of HLA-G expression in human gliomas:
an alternative strategy of immune escape. J Immunol (2002) 168(9):4772–80.
doi:10.4049/jimmunol.168.9.4772
64. Kren L, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T, et al. Pro-
duction of immune-modulatory nonclassical molecules HLA-G and HLA-E
by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role
in innate immunity? J Neuroimmunol (2010) 220(1–2):131–5. doi:10.1016/j.
jneuroim.2010.01.014
65. Kren L, Slaby O, Muckova K, Lzicarova E, Sova M, Vybihal V, et al. Expres-
sion of immune-modulatory molecules HLA-G and HLA-E by tumor cells in
glioblastomas: an unexpected prognostic significance? Neuropathology (2011)
31(2):129–34. doi:10.1111/j.1440-1789.2010.01149.x
66. Wastowski IJ, Simoes RT, Yaghi L, Donadi EA, Pancoto JT, Poras I, et al.
Human leukocyte antigen-G is frequently expressed in glioblastoma and
may be induced in vitro by combined 5-aza-2’-deoxycytidine and interferon-
gamma treatments: results from a multicentric study. Am J Pathol (2013)
182(2):540–52. doi:10.1016/j.ajpath.2012.10.021
67. Guo QY, Chen BG, Ruan YY, Lin A, Yan WH. HLA-G expression is irrele-
vant to prognosis in patients with acute myeloid leukemia. Leuk Res (2011)
35(10):1350–4. doi:10.1016/j.leukres.2011.05.036
68. Locafaro G, Amodio G, Tomasoni D, Tresoldi C, Ciceri F, Gregori S. HLA-G
expression on blasts and tolerogenic cells in patients affected by acute myeloid
leukemia. J Immunol Res (2014) 2014:636292. doi:10.1155/2014/636292
69. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression
is associated with an unfavorable outcome and immunodeficiency in chronic
lymphocytic leukemia. Blood (2005) 105(4):1694–8. doi:10.1182/blood-2004-
08-3335
70. Rebmann V, Nuckel H, Duhrsen U, Grosse-Wilde H. HLA-G in B-chronic
lymphocytic leukaemia: clinical relevance and functional implications. Semin
Cancer Biol (2007) 17(6):430–5. doi:10.1016/j.semcancer.2007.06.011
71. Giannopoulos K, Dmoszynska A, Bojarska-Junak A, Schmitt M, Rolinski J.
Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia
(B-CLL). Folia Histochem Cytobiol (2008) 46(4):457–60. doi:10.2478/v10042-
008-0072-x
72. Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression
in B chronic lymphocytic leukemia: a new prognostic marker? Hematology
(2009) 14(2):101–5. doi:10.1179/102453309X385197
73. Attia MA, Nosair NA, Gawally A, Elnagar G, Elshafey EM. HLA-G expression as
a prognostic indicator in B-cell chronic lymphocytic leukemia. Acta Haematol
(2014) 132(1):53–8. doi:10.1159/000353757
74. Kleinberg L, Florenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, et al.
Expression of HLA-G in malignant mesothelioma and clinically aggressive
breast carcinoma. Virchows Arch (2006) 449(1):31–9. doi:10.1007/s00428-005-
0144-7
75. Provatopoulou X, Kalogera E, Sagkriotis A, Zagouri F, Nonni A, Zografos GC,
et al. Soluble human leukocyte antigen-G expression in patients with ductal
and lobular breast malignancy. Anticancer Res (2012) 32(3):1021–6.
76. Dardano A, Rizzo R, Polini A, Stignani M, Tognini S, Pasqualetti G, et al. Soluble
human leukocyte antigen-g and its insertion/deletion polymorphism in papil-
lary thyroid carcinoma: novel potential biomarkers of disease? J Clin Endocrinol
Metab (2012) 97(11):4080–6. doi:10.1210/jc.2012-2231
77. Zhu CB, Wang CX, Zhang X, Zhang J, Li W. Serum sHLA-G levels: a useful
indicator in distinguishing colorectal cancer from benign colorectal diseases.
Int J Cancer (2011) 128(3):617–22. doi:10.1002/ijc.25372
78. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, et al. Solu-
ble HLA-G molecules increase during acute leukemia, especially in subtypes
affecting monocytic and lymphoid lineages. Neoplasia (2006) 8(3):223–30.
doi:10.1593/neo.05703
79. Morandi F, Scaruffi P, Gallo F, Stigliani S, Moretti S, Bonassi S, et al. Bone
marrow-infiltrating human neuroblastoma cells express high levels of calpro-
tectin and HLA-G proteins. PLoS One (2012) 7(1):e29922. doi:10.1371/journal.
pone.0029922
80. Eskandari-Nasab E, Hashemi M, Hasani SS, Omrani M, Taheri M, Mash-
hadi MA. Association between HLA-G 3’UTR 14-bp ins/del polymorphism
and susceptibility to breast cancer. Cancer Biomark (2013) 13(4):253–9.
doi:10.3233/CBM-130364
81. Jeong S, Park S, Park BW, Park Y, Kwon OJ, Kim HS. Human leukocyte antigen-
G (HLA-G) polymorphism and expression in breast cancer patients. PLoS One
(2014) 9(5):e98284. doi:10.1371/journal.pone.0098284
www.frontiersin.org February 2015 | Volume 6 | Article 9 | 9
Dias et al. HLA-G and disease association
82. Ge YZ, Ge Q, Li MH, Shi GM, Xu X, Xu LW, et al. Association between human
leukocyte antigen-G 14-bp insertion/deletion polymorphism and cancer risk:
a meta-analysis and systematic review. Hum Immunol (2014) 75(8):827–32.
doi:10.1016/j.humimm.2014.06.004
83. Teixeira AC, Mendes-Junior CT, Souza FF, Marano LA, Deghaide NH, Ferreira
SC, et al. The 14bp-deletion allele in the HLA-G gene confers susceptibility
to the development of hepatocellular carcinoma in the Brazilian population.
Tissue Antigens (2013) 81(6):408–13. doi:10.1111/tan.12097
84. Jiang Y, Chen S, Jia S, Zhu Z, Gao X, Dong D, et al. Association of HLA-G 3’
UTR 14-bp insertion/deletion polymorphism with hepatocellular carcinoma
susceptibility in a Chinese population. DNA Cell Biol (2011) 30(12):1027–32.
doi:10.1089/dna.2011.1238
85. Lau DT, Norris MD, Marshall GM, Haber M, Ashton LJ. HLA-G polymor-
phisms, genetic susceptibility, and clinical outcome in childhood neurob-
lastoma. Tissue Antigens (2011) 78(6):421–7. doi:10.1111/j.1399-0039.2011.
01781.x
86. Castelli EC, Mendes-Junior CT, Deghaide NH, de Albuquerque RS, Muniz YC,
Simoes RT, et al. The genetic structure of 3’untranslated region of the HLA-
G gene: polymorphisms and haplotypes. Genes Immun (2010) 11(2):134–41.
doi:10.1038/gene.2009.74
87. Ghandri N, Gabbouj S, Farhat K, Bouaouina N, Abdelaziz H, Nouri A,
et al. Association of HLA-G polymorphisms with nasopharyngeal carcinoma
risk and clinical outcome. Hum Immunol (2011) 72(2):150–8. doi:10.1016/j.
humimm.2010.10.006
88. Castelli EC, Mendes-Junior CT,Viana de Camargo JL, Donadi EA. HLA-G poly-
morphism and transitional cell carcinoma of the bladder in a Brazilian pop-
ulation. Tissue Antigens (2008) 72(2):149–57. doi:10.1111/j.1399-0039.2008.
01091.x
89. Rolfsen GB, Castelli EC, Donadi EA, Duarte RA, Soares CP. HLA-G polymor-
phism and breast cancer. Int J Immunogenet (2014) 41(2):143–8. doi:10.1111/
iji.12092
90. Chen Y, Gao XJ, Deng YC, Zhang HX. Relationship between HLA-G gene
polymorphism and the susceptibility of esophageal cancer in Kazakh and Han
nationality in Xinjiang. Biomarkers (2012) 17(1):9–15. doi:10.3109/1354750X.
2011.633242
91. de Oliveira Crispim JC, Silva TG, Souto FJ, Souza FF, Bassi CL, Soares CP,
et al. Upregulation of soluble and membrane-bound human leukocyte anti-
gen G expression is primarily observed in the milder histopathological stages
of chronic hepatitis C virus infection. Hum Immunol (2012) 73(3):258–62.
doi:10.1016/j.humimm.2011.12.004
92. Amiot L, Vu N, Rauch M, L’Helgoualc’h A, Chalmel F, Gascan H, et al. Expres-
sion of HLA-G by mast cells is associated with hepatitis C virus-induced liver
fibrosis. J Hepatol (2014) 60(2):245–52. doi:10.1016/j.jhep.2013.09.006
93. Weng PJ, Fu YM, Ding SX, Xu DP, Lin A, Yan WH. Elevation of plasma soluble
human leukocyte antigen-G in patients with chronic hepatitis C virus infection.
Hum Immunol (2011) 72(5):406–11. doi:10.1016/j.humimm.2011.02.008
94. Souto FJ, Crispim JC, Ferreira SC, da Silva AS, Bassi CL, Soares CP, et al. Liver
HLA-G expression is associated with multiple clinical and histopathological
forms of chronic hepatitis B virus infection. J Viral Hepat (2011) 18(2):102–5.
doi:10.1111/j.1365-2893.2010.01286.x
95. Shi WW, Lin A, Xu DP, Bao WG, Zhang JG, Chen SY, et al. Plasma soluble
human leukocyte antigen-G expression is a potential clinical biomarker in
patients with hepatitis B virus infection. Hum Immunol (2011) 72(11):1068–73.
doi:10.1016/j.humimm.2011.06.012
96. Han Q, Li N, Zhu Q, Li Z, Zhang G, Chen J, et al. Association of serum soluble
human leukocyte antigen-G levels with chronic hepatitis B virus infection. Clin
Exp Med (2014) 14(1):35–43. doi:10.1007/s10238-012-0214-5
97. Cordero EA,Veit TD, da Silva MA, Jacques SM, Silla LM, Chies JA. HLA-G poly-
morphism influences the susceptibility to HCV infection in sickle cell disease
patients. Tissue Antigens (2009) 74(4):308–13. doi:10.1111/j.1399-0039.2009.
01331.x
98. da Silva GK, Vianna P, Veit TD, Crovella S, Catamo E, Cordero EA, et al. Influ-
ence of HLA-G polymorphisms in human immunodeficiency virus infection
and hepatitis C virus co-infection in Brazilian and Italian individuals. Infect
Genet Evol (2014) 21:418–23. doi:10.1016/j.meegid.2013.12.013
99. Kim SK, Chung JH, Jeon JW, Park JJ, Cha JM, Joo KR, et al. Association between
HLA-G 14-bp insertion/deletion polymorphism and hepatocellular carcinoma
in Korean patients with chronic hepatitis B viral infection. Hepatogastroenterol-
ogy (2013) 60(124):796–8. doi:10.5754/hge11180
100. Sartelet H, Schleiermacher D, Le-Hesran JY, Graesslin O, Gaillard D, Fe M, et al.
Less HLA-G expression in Plasmodium falciparum-infected third trimester pla-
centas is associated with more natural killer cells. Placenta (2005) 26(6):505–11.
doi:10.1016/j.placenta.2004.08.006
101. Sadissou I, d’Almeida T, Cottrell G, Luty A, Krawice-Radanne I, Massougbodji
A, et al. High plasma levels of HLA-G are associated with low birth weight
and with an increased risk of malaria in infancy. Malar J (2014) 13(1):312.
doi:10.1186/1475-2875-13-312
102. Garcia A, Milet J, Courtin D, Sabbagh A, Massaro JD, Castelli EC, et al. Asso-
ciation of HLA-G 3’UTR polymorphisms with response to malaria infection:
a first insight. Infect Genet Evol (2013) 16:263–9. doi:10.1016/j.meegid.2013.
02.021
103. Sabbagh A, Courtin D, Milet J, Massaro JD, Castelli EC, Migot-Nabias F, et al.
Association of HLA-G 3’ untranslated region polymorphisms with antibody
response against Plasmodium falciparum antigens: preliminary results. Tissue
Antigens (2013) 82(1):53–8. doi:10.1111/tan.12140
104. Courtin D, Milet J, Sabbagh A, Massaro JD, Castelli EC, Jamonneau V, et al.
HLA-G 3’ UTR-2 haplotype is associated with human African trypanosomiasis
susceptibility. Infect Genet Evol (2013) 17:1–7. doi:10.1016/j.meegid.2013.03.
004
105. Ayo CM, Dalalio MM, Visentainer JE, Reis PG, Sippert EA, Jarduli LR, et al.
Genetic susceptibility to Chagas disease: an overview about the infection and
about the association between disease and the immune response genes. Biomed
Res Int (2013) 2013:284729. doi:10.1155/2013/284729
106. Marin-Neto JA, Rassi A Jr. Update on Chagas heart disease on the first cen-
tennial of its discovery. Rev Esp Cardiol (2009) 62(11):1211–6. doi:10.1016/
S1885-5857(09)73346-8
107. Dias FC, Mendes-Junior CT, da Silva MC, Tristão FSM, Dellalibera-Joviliano
R, Moreau P, et al. Human leukocyte antigen-G (HLA-G) and its murine func-
tional homolog Qa2 in the Trypanosoma cruzi infection. Mediators Inflamm
(2014) 2014:595289. doi:10.1155/2014/595829
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest. The Review Editor, Joel LeMaoult, declares that
despite having co-authored a manuscript and being affiliated with the same insti-
tution as author Philippe Moreau, there has been no conflict of interest during the
review and handling of this manuscript.
Received: 03 October 2014; accepted: 07 January 2015; published online: 02 February
2015.
Citation: Dias FC, Castelli EC, Collares CVA, Moreau P and Donadi EA (2015) The
role of HLA-G molecule and HLA-G gene polymorphisms in tumors, viral hepatitis,
and parasitic diseases. Front. Immunol. 6:9. doi: 10.3389/fimmu.2015.00009
This article was submitted to Immunological Tolerance, a section of the journal Frontiers
in Immunology.
Copyright © 2015 Dias, Castelli, Collares, Moreau and Donadi. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | Immunological Tolerance February 2015 | Volume 6 | Article 9 | 10
